STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co Inc - MRK STOCK NEWS

Welcome to our dedicated news page for Merck & Co (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co's position in the market.

News
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Rhea-AI Summary
Merck's Phase 3 KEYNOTE-A18 trial with KEYTRUDA plus CRT shows significant improvement in OS for patients with high-risk locally advanced cervical cancer. The combination therapy met its primary endpoint of overall survival, demonstrating a statistically significant and clinically meaningful benefit compared to CRT alone. The safety profile was consistent with previous studies, with no new safety signals identified. These results support the FDA's approval of KEYTRUDA in combination with CRT for the treatment of patients with FIGO Stage III-IVA cervical cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
News
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Rhea-AI Summary
Merck (MRK) reaffirms its commitment to reducing the global burden of HPV-related diseases by announcing plans to develop a new multi-valent HPV vaccine and conduct clinical trials for a single-dose regimen of GARDASIL 9. The company aims to impact the burden of certain HPV-related cancers and diseases by expanding protection and supply capacity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
clinical trial
-
News
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Rhea-AI Summary
Merck (MRK) acquires Harpoon Therapeutics, broadening its oncology pipeline with T-cell engagers like MK-6070 targeting DLL3. MK-6070 is in Phase 1/2 trials for small cell lung cancer (SCLC) and neuroendocrine tumors. Merck records a $650 million charge for the acquisition, impacting non-GAAP EPS by $0.26 per share for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
News
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Rhea-AI Summary
Gilead Sciences and Merck announce positive Phase 2 clinical study results for a potential long-acting oral combination treatment for people with HIV. The investigational combination of islatravir and lenacapavir maintained a high rate of viral suppression at 24 weeks, supporting its development as a once-weekly oral regimen. This novel treatment option aims to address adherence and stigma challenges faced by individuals with HIV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
clinical trial
-
News
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference
Rhea-AI Summary
Merck (MRK) announces Jannie Oosthuizen's participation in fireside chat at Barclays Global Healthcare Conference. The presentation is open to investors, analysts, media, and the public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
conferences
-
News
Merck to Participate in the Leerink Partners Global Biopharma Conference 2024
Rhea-AI Summary
Merck (MRK) to present at Leerink Partners Global Biopharma Conference 2024. Dr. Marjorie Green to discuss oncology developments. Live webcast available for investors and the public.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
conferences
News
Merck to Participate in the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Merck (NYSE: MRK) announces Joseph Romanelli's participation in a fireside chat at the TD Cowen 44th Annual Health Care Conference on March 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences
-
News
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
Rhea-AI Summary
Merck (MRK) receives a positive opinion for KEYTRUDA in treating resectable non-small cell lung cancer in Europe based on the Phase 3 KEYNOTE-671 trial results, showing significant improvements in overall survival and event-free survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
News
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
Rhea-AI Summary
Merck's KEYTRUDA plus chemotherapy shows significant improvement in endometrial carcinoma treatment, with FDA accepting sBLA for priority review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
News
Merck Animal Health to Acquire Elanco’s Aqua Business
Rhea-AI Summary
Merck Animal Health, a division of Merck & Co., Inc., is set to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, expanding its aqua portfolio with innovative products and technology solutions. The acquisition includes aqua manufacturing facilities, a research facility, and a portfolio of medicines, vaccines, and supplements for aquatic species. The deal is expected to be completed by mid-year 2024, subject to regulatory approvals and customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
acquisition
Stock MRK logo
Merck & Co Inc

NYSE:MRK

MRK Rankings

#24 Ranked by Market Cap
#1895 Ranked by Stock Gains
#1274 Ranked by Dividends

MRK Stock Data

318.50B
2.53B
0.05%
78.56%
0.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Kenilworth

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.